Fairmount Funds Management LLC
In its 13F for Q2 2026 (holdings as of June 30, 2026, filed August 14, 2026), Fairmount Funds Management LLC reported 12 stock positions worth $1.5 billion. Its top holding was Oruka Therapeutics (ORKA) at 23.3% of the portfolio, followed by Dianthus Therapeutics (DNTH, 16.3%) and Damora Therapeutics (DMRA, 15.0%). Compared with Q1 2026, it opened 1 new position, sold out of 1 and added to 1. The biggest buy was a new position in Faeth Therapeutics (FTH) and the biggest sale an exit from Spyre Therapeutics (SYRE).
- Most Recent 13F
- Q2 2026
- Location
- WEST CONSHOHOCKEN, PA
- CIK
- 0001802528
- Portfolio Value
- $1.5B (Q2 2026)
- SEC Filing
- 0001104659-26-096405 ↗ filed Aug 14, 2026
Holdings Value
Holdings 12 stocks · $1.5B
| ORKA Oruka Therapeutics Inc. | 23.31% | 3,705,262 | $352.6M | No change |
| DNTH Dianthus Therapeutics Inc. | 16.35% | 2,537,191 | $247.3M | No change |
| DMRA Damora Therapeutics Inc. | 14.98% | 8,713,000 | $226.6M | No change |
| COGT Cogent Biosciences Inc. | 14.08% | 5,503,418 | $213.0M | No change |
| JBIO Jade Biosciences Inc. | 6.69% | 4,553,494 | $101.2M | No change |
| ELVN Enliven Therapeutics Inc. | 6.22% | 1,855,644 | $94.2M | No change |
| VRDN Viridian Therapeutics Inc. | 6.18% | 5,090,928 | $93.5M | Add +30.1% |
| ZBIO Zenas Biopharma Inc. | 3.96% | 2,359,025 | $59.9M | No change |
| CBIO Crescent Biopharma Inc. | 3.27% | 2,747,866 | $49.5M | No change |
| APGE Apogee Therapeutics Inc. | 2.62% | 298,647 | $39.6M | No change |
| FTH Faeth Therapeutics Inc. | 1.19% | 722,020 | $18.1M | New |
| IKT Inhibikase Therapeutics Inc. | 1.16% | 8,625,000 | $17.5M | No change |
Portfolio Sells Q1 2026 → Q2 2026
| SYRE Spyre Therapeutics Inc. | Sold out | 0.00% | −14.64 |
Portfolio Buys Q1 2026 → Q2 2026
All Filings
| Quarter | Positions | 13F Reported Value | Top Holdings |
|---|---|---|---|
| Q2 2026 | 12 | $1.5B | ORKA, DNTH, DMRA, COGT, JBIO |
| Q1 2026 | 12 | $1.4B | DMRA, DNTH, COGT, SYRE, ORKA |
| Q4 2025 | 13 | $1.3B | COGT, APGE, SYRE, VRDN, ORKA |
| Q3 2025 | 17 | $1.1B | DNTH, COGT, AXSM, APGE, ELVN |
| Q2 2025 | 17 | $771.9M | APGE, AXSM, ELVN, SRRK, SYRE |
| Q1 2025 | 15 | $644.6M | AXSM, APGE, SYRE, ELVN, NUVL |
| Q4 2024 | 17 | $1.0B | AXSM, NUVL, SYRE, APGE, SRRK |
| Q3 2024 | 15 | $1.2B | AXSM, NUVL, APGE, SYRE, ELVN |
| Q2 2024 | 13 | $885.1M | AXSM, NUVL, SYRE, APGE, ELVN |
| Q1 2024 | 15 | $917.4M | AXSM, NUVL, APGE, DNTH, KNSA |